Pharmacological characterization of the novel selective kappa opioid receptor agonists 10-Iodo-Akuammicine and 10-Bromo-akuammicine in mice
- 23 January 2025
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 268, 110316
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (R35GM147005)
- National Institutes of Health
- National Institute on Drug Abuse (R01 DA041359)
- National Institute on Drug Abuse (R01 DA056581)
- National Institute on Drug Abuse (P30DA013429)
This publication has 54 references indexed in Scilit:
- Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist2021
- Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans2020
- Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients2020
- Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology2020
- Kappa Opioid Agonist-Induced Diuresis: Characteristics, Mechanisms, and Beyond2020
- Kappa opioids and the modulation of painPsychopharmacology, 2010
- Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humansPsychopharmacology, 2001
- Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retentionGastroenterology, 1995
- In-vivo studies on kappa opioid receptorsTrends in Pharmacological Sciences, 1986
- [3H]U-69593 a highly selective ligand for the opioid κ receptorEuropean Journal of Pharmacology, 1985